Kristen Fortney

CIK: 0002032751

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

BIOA

BioAge Labs, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

BIOA
BioAge Labs, Inc.
Feb 17, 2026
Award(A)
Stock Option (Right to Buy)
Direct
330K shares-
BIOA
BioAge Labs, Inc.
Jan 13, 2026
Sale(S)
Direct
233.1K shares at avg. $18.12$4.2M
BIOA
BioAge Labs, Inc.
Feb 18, 2025
Award(A)
Stock Option (Right to Buy)
Direct
530K shares-
BIOA
BioAge Labs, Inc.
Sep 25, 2024
Award(A)
Stock Option (Right to Buy)
Direct
424.8K shares-
BIOA
BioAge Labs, Inc.
Apr 17, 2024
Award(A)
Stock Option (Right to Buy)
Direct
708K shares-

		Type	Shares	Price		Ownership
Feb 17, 2026	BIOA BioAge Labs, Inc.	Award(A) Stock Option (Right to Buy)	330,000	-	-	Direct
Jan 13, 2026	BIOA BioAge Labs, Inc.	Sale(S)	233,107	$18.12	$4,223,036	Direct
Feb 18, 2025	BIOA BioAge Labs, Inc.	Award(A) Stock Option (Right to Buy)	530,000	-	-	Direct
Sep 25, 2024	BIOA BioAge Labs, Inc.	Award(A) Stock Option (Right to Buy)	424,827	-	-	Direct
Apr 17, 2024	BIOA BioAge Labs, Inc.	Award(A) Stock Option (Right to Buy)	708,044	-	-	Direct

1-5 of 5 transactions

About Fortney Kristen

Fortney Kristen (SEC CIK 0002032751) files insider reports with the SEC as Chief Executive Officer of BioAge Labs, Inc. (BIOA).

Signal8 holds 5 ownership filings by Fortney Kristen (1 Form 3, 4 Form 4), filed between Sep 25, 2024 and Feb 19, 2026. Those filings report 5 transactions, from Apr 17, 2024 to Feb 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Fortney Kristen's filings is in EMERYVILLE, CA.

Recent filings by Fortney Kristen

Feb 17, 2026: Grant or award of BIOA derivative securities (Form 4, code A).
Jan 13, 2026: Open-market sale of BIOA shares (Form 4, code S).
Feb 18, 2025: Grant or award of BIOA derivative securities (Form 4, code A).
Sep 25, 2024: Grant or award of BIOA derivative securities (Form 4, code A).
Apr 17, 2024: Grant or award of BIOA derivative securities (Form 4, code A).

Other insiders filing for BioAge Labs, Inc. (BIOA)

Barton Shane, Principal Accounting Officer
Pande Vijay Satyanand, Director
Hemrajani Rekha, Director
HEALY JAMES, Director
ENRIGHT PATRICK G, Director
Davidson Michael H., Director

How to read Form 4 transaction codes